|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Belumosudil>> Market Analysis Reports |
Market Analysis Reports of Belumosudil |
|
Global Graft vs. Host Disease (GvHD) Stem Cell Therapy Market Growth (Status and Outlook) 2024-2030 ... Therapy players cover Osiris Therapeutics, Belumosudil, UChicago Medicine, Leukemia & Lymphoma Society ... , its market penetration. Osiris Therapeutics Belumosudil UChicago Medicine Leukemia & Lymphoma Society ... Scleroderma - Pipeline Insight, 2021 ... Vedotin IgPro20 ARG201 Dersimelagon (MT-7117) Belumosudil Belimumab Abatacept CAM2043 Tofacitinib Sarilumab ... Global Systemic Scleroderma Treatment Market Size study, by Drug Class (Immunosuppressors, Phosphodiesterase 5 inhibitors – PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers and Others), and Regional Forecasts 2021-2027 ... . for its novel drug candidate, Belumosudil (KD025), which is developed for the ... Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Systemic Sclerosis (Scleroderma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - ... Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Bone Marrow Transplant Rejection Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - ... Graft vs Host Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034 The 7 major Graft vs Host Disease markets reached a value of US$ 1.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.2 Billion by 2034, exhibiting a growth rate (CAGR) of 14.6% during 2024-2034. The Graft vs Host Disease Market ... |